Cancer immunotherapy biotech Unum Therapeutics files for an $86 million IPO – Nasdaq
Nasdaq |
Cancer immunotherapy biotech Unum Therapeutics files for an $86 million IPO
Nasdaq Unum Therapeutics, which is developing antibody-coupled T cell immunotherapies for cancers, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company was founded in 2014 and plans to list on … |
